Discontinued — last reported Q3 '25
Non-Controlling Interests
Royalty Pharma Non-Controlling Interests decreased by 5.9% to $3.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.7%, from $3.10B to $3.05B. Over 5 years (FY 2020 to FY 2025), Non-Controlling Interests shows a downward trend with a -8.6% CAGR.
Analysis
How to read this metric
An increase suggests the company has expanded its consolidated operations through partially-owned subsidiaries, while a decrease may indicate buyouts of minority stakes.
Detailed definition
This represents the portion of equity in a subsidiary not attributable, directly or indirectly, to the parent company. I...
Peer comparison
Common in large conglomerates or companies with complex joint venture structures; peers often report this as a small fraction of total equity.
noncontrolling_interestsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.67B | $4.59B | $4.47B | $4.36B | $4.38B | $4.26B | $3.90B | $3.87B | $3.53B | $3.45B | $3.56B | $3.36B | $3.28B | $3.39B | $3.40B | $3.10B | $3.16B | $3.21B | $3.24B | $3.05B |
| QoQ Change | — | -1.7% | -2.6% | -2.4% | +0.4% | -2.7% | -8.6% | -0.7% | -8.7% | -2.4% | +3.2% | -5.4% | -2.6% | +3.5% | +0.2% | -8.7% | +1.8% | +1.6% | +1.0% | -5.9% |
| YoY Change | — | — | — | — | -6.2% | -7.2% | -12.9% | -11.4% | -19.4% | -19.2% | -8.7% | -13.0% | -7.3% | -1.7% | -4.6% | -7.8% | -3.7% | -5.4% | -4.6% | -1.7% |
Non-Controlling Interests at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's non-controlling interests?
- Royalty Pharma (RPRX) reported non-controlling interests of $3.05B in Q1 2026.
- How has Royalty Pharma's non-controlling interests changed year-over-year?
- Royalty Pharma's non-controlling interests decreased by 1.7% year-over-year, from $3.10B to $3.05B.
- What is the long-term trend for Royalty Pharma's non-controlling interests?
- Over 5 years (2020 to 2025), Royalty Pharma's non-controlling interests has grown at a -8.6% compound annual growth rate (CAGR), from $5.08B to $3.24B.
- What does non-controlling interests mean?
- The portion of a subsidiary's equity owned by outside parties rather than the parent company.